文献速递主动脉疾病内脏/肾动脉与血管畸形

开窗/分支支架治疗夹层后胸腹主动脉瘤的中期结果

Mid-Term Results of Fenestrated/Branched Stent Grafting to Treat Post-dissection Thoraco-abdominal Aneurysms.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-09-01

回顾性分析两个血管中心2010年1月至2017年4月71例夹层后胸腹主动脉瘤患者接受开窗/分支支架腔内修复的中期结果。技术成功68/71(95.8%),院内死亡4例(5.6%),围手术期并发症19.6%,随访期间无破裂,但再干预率较高。

要点

  • 技术成功68/71(95.8%),院内死亡4例(5.6%),围手术期并发症19.6%。
  • 12、24、36个月累积生存率分别为84.7±4.5%、80.7±5.1%、70.0±6.7%。
  • 12、24、36个月免于再干预率分别为80.7±5.3%、63.0±6.9%、52.6±8.0%。

核心结论

  • 开窗/分支支架腔内修复治疗夹层后胸腹主动脉瘤可行,围手术期死亡率和并发症率低。
  • 中期结果显示动脉瘤囊回缩率高,但再干预率显著,需要严格随访。
  • 作者建议目标血管使用更长的桥接覆膜支架。

研究设计与样本

  • 回顾性分析前瞻性维护数据库,纳入2010年1月至2017年4月在两个有腔内技术经验的血管机构接受开窗/分支支架腔内修复的所有夹层后胸腹主动脉瘤患者,共71例连续患者(男性56例,平均年龄63.8±10.6岁)。

主要发现

  • 技术成功68/71(95.8%),院内死亡4例(5.6%),围手术期并发症19.6%。
  • 3例(4.2%)发生严重脊髓缺血,其中1例在术后12个月发生。
  • 平均随访25.3个月(1-77个月);12、24、36个月累积生存率分别为84.7±4.5%、80.7±5.1%、70.0±6.7%。
  • 12、24、36个月估计免于再干预率分别为80.7±5.3%、63.0±6.9%、52.6±8.0%;再干预主要原因为内脏/肾动脉内漏和需延伸的髂动脉内漏。
  • 目标血管闭塞8/261(3.1%)(肾动脉4例、肠系膜上动脉2例、腹腔干2例);随访期间平均动脉瘤囊回缩9.2±8.8 mm,随访超过12个月的患者假腔血栓形成率85.4%;随访期间无破裂发生。

临床怎么用

  • 作者认为开窗/分支支架腔内修复治疗夹层后胸腹主动脉瘤可行,围手术期死亡率和并发症率低。
  • 作者建议目标血管使用更长的桥接覆膜支架。
  • 作者指出由于再干预率显著,需要严格随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients surviving acute aortic dissection are at risk of developing a post-dissection thoraco-abdominal aortic aneurysm (PD-TAAA) during follow up, regardless of the type of treatment in the acute setting. Fenestrated and branched stent grafting (F/B-TEVAR) has been used with success to treat PD-TAAA, albeit reported only with short-term results. The aim of this study was to report mid-term results in a cohort of 71 patients. METHODS: This was a retrospective analysis of a prospectively maintained database including all patients with PD-TAAAs who underwent F/B-TEVAR within the period January 2010 - April 2017 at two vascular institutions experienced in endovascular techniques. RESULTS: A total of 71 consecutive patients (56 male, mean age 63.8 ± 10.6 years) were treated. Technical success was achieved in 68/71 (95.8%) patients. In hospital mortality was four (5.6%) patients. Peri-operative morbidity was 19.6%. Three (4.2%) patients developed severe spinal cord ischaemia, one of these patients 12 months post-operatively. Mean follow up was 25.3 months (1-77 months). Cumulative survival rates at 12, 24, and 36 months were 84.7 ± 4.5%, 80.7 ± 5.1%, and 70.0 ± 6.7%, respectively. Estimated freedom from re-intervention at 12, 24, and 36 months was 80.7 ± 5.3%, 63.0 ± 6.9%, and 52.6 ± 8.0%, respectively. The main reasons for re-intervention were endoleak from visceral/renal arteries and iliac endoleak requiring extension. Target vessel occlusion occurred in 8/261 (3.1%) vessels (renal artery n = 4; superior mesenteric artery n = 2; coeliac artery n = 2). Mean aneurysm sac regression during follow up was 9.2 ± 8.8 mm, with a false lumen thrombosis rate of 85.4% for patients with a follow up longer than 12 months. No ruptures occurred during follow up. CONCLUSION: F/B-TEVAR for post-dissection TAAA is feasible and associated with low peri-operative mortality and peri-operative morbidity. Mid-term results demonstrate a high rate of aneurysm sac regression. Rigorous follow up is required because of the significant re-intervention rate. Longer bridging covered stents for target vessels are advised.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Oikonomou K, Kasprzak P, Katsargyris A, et al. Mid-Term Results of Fenestrated/Branched Stent Grafting to Treat Post-dissection Thoraco-abdominal Aneurysms. Eur J Vasc Endovasc Surg. 2018. PMID: 30181064. doi:10.1016/j.ejvs.2018.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。